Findings of a 7-year study revolutionized the standard protocol for patient management by reducing toxicities for patients with metastatic renal cell carcinoma (mRCC).
Sunitinib, an agent approved for use in several cancers, could prove useful in treatment of thymic carcinoma when traditional chemotherapy fails.
A trial comparing pazopanib and sunitinib found pazopanib to have better safety and health-related quality-of-life profiles among persons with metastatic renal cell carcinoma.
Markers in primary tumors such as CA9, CD31, CD34, and VEGFR1/2 might serve as predictors of a good response to sunitinib treatment in patients with metastatic clear cell renal carcinoma (ccRCC).
Animal studies have suggested that sunitinib may promote cancer growth and metastasis, but this does not appear to happen in humans.
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Regorafenib, a new, targeted, oral drug, demonstrated the ability to control metastatic GIST, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies.
What is the role of sunitinib malate in the treatment of sarcomas?
Kidney cancer drugs in development could improve patients' quality of life and allow more effective treatment, according to Professor Robert Hawkins of Manchester University.
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
- Distress Management Tool Gets an Update, Patient Version
- PSA Screening Rates Level Off in United States
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|